# US 2026/0263430 A1 · Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263430 A1
- Document ID: US20260263430A1
- Status: Published application
- Kind: A1
- Application number: 19/674,658
- Filed: 2026-05-12
- Published: 2026-09-10
- Earliest claimed: 2020-02-21
- Assignees: The Florida State University Research Foundation, Inc.
- Applicants: Florida State University Research Foundation, Inc.
- Inventors: Eric Holmes; Gary Ostrander
- Web page: https://patentgrep.com/patent/US20260263430A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

## Claims

### Claim 1

A composition comprising (a) castanospermine or a prodrug thereof and (b) a sugar, a starch, or a combination thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the prodrug of castanospermine is celgosivir.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition comprises a composition for oral administration.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprises a tablet, lozenge, a capsule, a spray, a powder, or a liquid formulation.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition further comprises a permeability enhancer.

### Claim 6 (depends on 1)

The composition of claim 1, further comprising an additional agent effective for the treatment or prevention of a coronavirus infection.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising an additional agent effective for the treatment of one or more symptoms of a coronavirus infection.

### Claim 8 (depends on 1)

The composition of claim 1, wherein castanospermine or a prodrug thereof is from 0.1 weight percent to 45 weight percent of the composition.

### Claim 9 (depends on 1)

The composition of claim 1, wherein castanospermine or a prodrug thereof is from 1 weight percent to 15 weight percent of the composition.

### Claim 10

A composition for inhalation comprising castanospermine or a prodrug thereof and a carrier suitable for inhalation.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the prodrug of castanospermine is celgosivir.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the composition further comprises a permeability enhancer.

### Claim 13 (depends on 10)

The composition of claim 10, further comprising an additional agent effective for the treatment or prevention of a coronavirus infection.

### Claim 14 (depends on 10)

The composition of claim 10, further comprising an additional agent effective for the treatment of one or more symptoms of a coronavirus infection.

### Claim 15 (depends on 10)

The composition of claim 10, wherein castanospermine or a prodrug thereof is from 0.1 weight percent to 45 weight percent of the composition.

### Claim 16 (depends on 10)

The composition of claim 10, wherein castanospermine or a prodrug thereof is from 1 weight percent to 15 weight percent of the composition.

### Claim 17 (depends on 10)

The composition of claim 10, wherein the composition comprises a powder or spray.

### Claim 18 (depends on 10)

The composition of claim 10, wherein the carrier is suitable for nasal administration or intranasal administration.
